Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Reilly

Showing results (591-600 of 598) with videos related to

Pageof 60
Sort By:
You have reached the last page of results.This site can display upto 598 results.
ACS Medicinal Chemistry Letters|June 20, 2020
Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion ChannelPamela A Haile, Linda N Casillas, Michael J Bury, et al.
Nature Genetics|March 25, 2014
Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic typeLeora Witkowski, Jian Carrot-Zhang, Steffen Albrecht, et al.
ACS Medicinal Chemistry Letters|October 23, 2018
Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion ChannelPamela A Haile, Linda N Casillas, Michael J Bury, et al.
Nature|November 9, 2018
Design of amidobenzimidazole STING receptor agonists with systemic activityJoshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, et al.
Journal of Medicinal Chemistry|February 3, 2017
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory DiseasesPhilip A Harris, Scott B Berger, Jae U Jeong, et al.
Nature|May 31, 2019
Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activityJoshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, et al.
Circulation|June 18, 2013
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) StudyStuart J Connolly, Lars Wallentin, Michael D Ezekowitz, et al.
Journal of Medicinal Chemistry|April 24, 2019
Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) KinasePhilip A Harris, Nicolas Faucher, Nicolas George, et al.
Pageof 60

Showing results (591-600 of 598) with videos related to

Sort By:
Pageof 60
You have reached the last page of results.This site can display upto 598 results.
ACS Medicinal Chemistry Letters|June 20, 2020
Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion ChannelPamela A Haile, Linda N Casillas, Michael J Bury, et al.
Nature Genetics|March 25, 2014
Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic typeLeora Witkowski, Jian Carrot-Zhang, Steffen Albrecht, et al.
ACS Medicinal Chemistry Letters|October 23, 2018
Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion ChannelPamela A Haile, Linda N Casillas, Michael J Bury, et al.
Nature|November 9, 2018
Design of amidobenzimidazole STING receptor agonists with systemic activityJoshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, et al.
Journal of Medicinal Chemistry|February 3, 2017
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory DiseasesPhilip A Harris, Scott B Berger, Jae U Jeong, et al.
Nature|May 31, 2019
Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activityJoshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, et al.
Circulation|June 18, 2013
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) StudyStuart J Connolly, Lars Wallentin, Michael D Ezekowitz, et al.
Journal of Medicinal Chemistry|April 24, 2019
Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) KinasePhilip A Harris, Nicolas Faucher, Nicolas George, et al.
Pageof 60